Michael Bergamini Email & Phone Number

Fort Worth, TX, US

Consulting in ophthalmic drug and device R&D

Ocular Pharmacology

• Appointed to Graduate Faculty
• Appointed to the Academy of Medical Educators of the Texas College of Osteopathic Medicine
• Taught clinical & drug development to faculty, students, & staff of UNTHSC, UT Southwestern, UT Arlington, & John Peter Smith Health Network.

As an Executive-In-Residence (EIR) at the University of North Texas Health Science Center (UNTHSC), I, and the other EIRs, provided early stage entrepreneurial life science companies in the UNTHSC incubator with real-world, limited general business guidance for the critical early stages of pharmaceutical and medical device product development.

Identified industry sponsored clinical trials that meshed with the academic interests of Orthopaedic Surgery faculty and managed the efforts to be selected as a site. PIs and trials quadrupled, and the revenues increased ten-fold.

Co-Author of one of a series of 3 articles receiving the 2013 George W. Northup, DO, Medical Writing Award, as the best articles published in the Journal of the American Osteopathic Association in 2012.

• Executive oversight of all activities related to the conduct of pharmaceutical and medical device industry sponsored clinical trials at UNTHSC and its affiliated institutions. Developed relations, oversaw contract.
• Initiated a clinical trial Research Registry for UNT Health (medical practice plan) patients.
• Provided development expertise (CMC & clinical) and project management for a start-up that received $2 million from the Texas Emerging Technology Fund and was named a 2011 Small Business of the Year.
• Invited member of NIH NCATS Therapeutics for Rare and Neglected Diseases (TRND) panel of expert reviewers.

Valbonne, FR

Consulting services concerning posterior blepharitis and nitric oxide donation in the field of ophthalmology.

Valbonne, FR

Responsible for R&D, QRV, & Manufacturing (via CMOs) of Nicox, a new international ophthalmic company, aiming to build a diversified portfolio of therapeutic products addressing the needs of eyecare practitioners and patients around the world.

Geneva, Switzerland, CH

• Executive accountable for the development of new ophthalmic pharmaceutical products (recently focused on glaucoma) for the world leader in Ophthalmology. Direct the Project Team Captains to move projects through the.
• Led/mentored development activities and resolved resource conflicts leading to submission, approval, and launch of TRAVATAN®, VIGAMOX®, TRAVATAN® Dosing Aid, DUOTRAV®, TRAVATAN® Z, PATADAY®, and AZARGA™.

Geneva, Switzerland, CH

• Executive responsible for a consistent flow from European external sources (companies/institutions) of therapeutic product opportunities for development. Direct activities to ensure expedient evaluation and licensing.
• Negotiated license/supply agreement and 2 strategic alliances for potential breakthrough retinal therapies.

• CEO of the worldwide R&D center for a multinational pharmaceutical company specializing in ophthalmic (as well as dermatologic & ENT) therapeutics and ophthalmic surgical adjuncts. Directed biological R&D (cell.
• Initiated a project management system to control and directed task forces to develop and launch 2 new Rx (OFTALMOTRIM-DEXA®, OTIX®) and 2 dozen generics, a dozen OTC, and 2 dozen cosmeceutical products in domestic and.
• Revamped the focus, style, and pace of R&D such that Cusí was rated in the top 2 for innovation in Spain for 1991 & 1992, advanced 2 levels in the "Plan de Fomento Industria" into top 10%, and.
• Initiated the design and implementation of the first 24 hr/day pharmacovigilance program in Spain.
• Integrated Cusí R&D Center into Alcon R&D. Reduced head-count to 55 while finding positions for all affected personnel and maintaining schedule of regulatory submissions and product launches.

• Executive manager of worldwide R&D and pharmaceutical product maintenance for a multinational vision care company. Directed all pharmaceutical development, package development, analytical chemistry, microbiology.
• Initiated and led task forces to launch 6 new international and domestic OTC contact lens products that accounted for 40% of company’s contact lens care product sales. Developed strategy and led re-entry into.

• Director of all preclinical and clinical ophthalmic research, both for internal product development projects and for external contract projects, for a biotechnology firm specializing in the use of liposomes as novel.
• Directed the first external contract to achieve acceptance of a prototype formulation by a sponsor.
• Principal Investigator of a funded SBIR grant.

Dublin, Coolock, IE

• Manager of pharmacological research for the then world leader in ophthalmic pharmaceuticals. Planned and managed by objectives the activities of 4 Ph.D. investigators, designed projects and allocated resources using.
• Led the Glaucoma, Inflammation/Immune Regulation, and Cataract Research Programs as well as specific compound evaluation projects.
• Directed the evaluation of a novel New Chemical Entity from primary animal screening, through analytical and formulation development, preservative selection and effectiveness testing, and toxicological evaluation, to.

Legal Officer MarBksBklyn, Company XO, Rifle & Weapons Platoon Commander, PLC

Ph.D., Biomedical Sciences Doctoral Program - Pharmacology

B.S., Biology

Education record

Education record